# Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

> **NCT01221857** · PHASE1,PHASE2 · COMPLETED · sponsor: **Gamida Cell ltd** · enrollment: 12 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia (ALL)
- Acute Myelogenous Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Non-Hodgkin's Lymphoma
- Hodgkin's Disease

## Interventions

- **DRUG:** NiCord®

## Key facts

- **NCT ID:** NCT01221857
- **Lead sponsor:** Gamida Cell ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-09
- **Final completion:** 2013-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01221857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01221857, "Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01221857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*